{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T08:24:29Z","timestamp":1794817469533,"version":"4.9.1"},"publisher-location":"Cham","reference-count":123,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031972416","type":"print"},{"value":"9783031972423","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-97242-3_8","type":"book-chapter","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T20:23:46Z","timestamp":1755894226000},"page":"157-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Immune Modulatory Agents in the Treatment of Non-small Cell Lung Cancer"],"prefix":"10.1007","author":[{"given":"Amanda","family":"Reyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"4","key":"8_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","volume":"9","author":"C Mattiuzzi","year":"2019","unstructured":"Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9(4):217\u201322.","journal-title":"J Epidemiol Glob Health"},{"issue":"10299","key":"8_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354.","journal-title":"Lancet"},{"issue":"19","key":"8_CR3","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998\u20132006.","journal-title":"JAMA"},{"issue":"6165","key":"8_CR4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J. Cancer immunotherapy. Science. 2013;342(6165):1432\u20133.","journal-title":"Science"},{"issue":"5","key":"8_CR5","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol Tor Ont. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol Tor Ont"},{"issue":"8","key":"8_CR6","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321\u20138.","journal-title":"Ann Oncol"},{"issue":"19","key":"8_CR7","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"14","key":"8_CR8","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1\u2013selected patients with NSCLC. N Engl J Med. 2020;383(14):1328\u201339.","journal-title":"N Engl J Med"},{"issue":"10274","key":"8_CR9","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer A, Kilickap S, G\u00fcm\u00fc\u015f M, Bondarenko I, \u00d6zg\u00fcro\u011flu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592\u2013604.","journal-title":"Lancet"},{"issue":"21","key":"8_CR10","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in advanced non\u2013small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"8_CR11","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol. 2023;41(6):1213\u201327.","journal-title":"J Clin Oncol"},{"issue":"22","key":"8_CR12","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"7","key":"8_CR13","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337.","journal-title":"Lancet Oncol"},{"issue":"11","key":"8_CR14","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","volume":"28","author":"M Gogishvili","year":"2022","unstructured":"Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022;28(11):2374\u201380.","journal-title":"Nat Med"},{"issue":"2","key":"8_CR15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198\u2013211.","journal-title":"Lancet Oncol"},{"issue":"6","key":"8_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer. N Engl J Med. 2023;389(6):491\u2013503.","journal-title":"N Engl J Med"},{"issue":"21","key":"8_CR17","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"6","key":"8_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL, Mart\u00ednez-Mart\u00ed A, Bernab\u00e9 R, Bosch-Barrera J, et al. Perioperative nivolumab and chemotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med. 2023;389(6):504\u201313.","journal-title":"N Engl J Med"},{"issue":"18","key":"8_CR19","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non\u2013small-cell lung cancer. N Engl J Med. 2023;389(18):1672\u201384.","journal-title":"N Engl J Med"},{"issue":"10308","key":"8_CR20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, Cs\u0151szi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344\u201357.","journal-title":"Lancet"},{"issue":"6","key":"8_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","volume":"21","author":"CA Shu","year":"2020","unstructured":"Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):786\u201395.","journal-title":"Lancet Oncol"},{"issue":"10","key":"8_CR22","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O\u2019Brien","year":"2022","unstructured":"O\u2019Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274\u201386.","journal-title":"Lancet Oncol"},{"issue":"1","key":"8_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398","volume":"8","author":"HM Kluger","year":"2020","unstructured":"Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. J Immunother Cancer. 2020;8(1):e000398.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"8_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20(1):25\u201339.","journal-title":"Nat Rev Immunol"},{"issue":"6280","key":"8_CR25","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139.","journal-title":"Science"},{"issue":"2","key":"8_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, et al. Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167(2):397\u2013404.e9.","journal-title":"Cell"},{"issue":"8","key":"8_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/intimm\/dxw019","volume":"28","author":"N Riaz","year":"2016","unstructured":"Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. The role of neoantigens in response to immune checkpoint blockade. Int Immunol. 2016;28(8):411\u20139.","journal-title":"Int Immunol"},{"issue":"1","key":"8_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344.","journal-title":"Cell"},{"issue":"4","key":"8_CR29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","volume":"20","author":"D Zingg","year":"2017","unstructured":"Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 2017;20(4):854\u201367.","journal-title":"Cell Rep"},{"issue":"12","key":"8_CR30","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1158\/1078-0432.CCR-16-1946","volume":"23","author":"C Pereira","year":"2017","unstructured":"Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, et al. Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition. Clin Cancer Res. 2017;23(12):3203\u201313.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"8_CR31","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7(12):1420\u201335.","journal-title":"Cancer Discov"},{"issue":"3","key":"8_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"8_CR33","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","volume":"3","author":"DS Thommen","year":"2015","unstructured":"Thommen DS, Schreiner J, M\u00fcller P, Herzig P, Roller A, Belousov A, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res. 2015;3(12):1344\u201355.","journal-title":"Cancer Immunol Res"},{"issue":"6230","key":"8_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74\u201380.","journal-title":"Science"},{"issue":"12","key":"8_CR35","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/annonc\/mdz224","volume":"30","author":"N Chaput","year":"2019","unstructured":"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2019;30(12):2012.","journal-title":"Ann Oncol"},{"issue":"6","key":"8_CR36","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437\u201344.","journal-title":"Ann Oncol"},{"issue":"4","key":"8_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.21037\/atm.2019.11.52","volume":"8","author":"X Chen","year":"2020","unstructured":"Chen X, Su C, Ren S, Zhou C, Jiang T. Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes. Ann Transl Med. 2020;8(4):141.","journal-title":"Ann Transl Med"},{"issue":"7","key":"8_CR38","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822\u201335.","journal-title":"Cancer Discov"},{"issue":"24","key":"8_CR39","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"},{"issue":"21","key":"8_CR40","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.22.00912","volume":"40","author":"KL Reckamp","year":"2022","unstructured":"Reckamp KL, Redman MW, Dragnev KH, Minichiello K, Villaruz LC, Faller B, et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A. J Clin Oncol. 2022;40(21):2295\u2013306.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"8_CR41","doi-asserted-by":"publisher","first-page":"TPS8657","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8657","volume":"42","author":"KL Reckamp","year":"2024","unstructured":"Reckamp KL, Redman MW, Dragnev KH, Iams WT, Henick BS, Miao J, et al. SWOG S2302, PRAGMATICA-LUNG: a prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer. J Clin Oncol. 2024;42(16_suppl):TPS8657.","journal-title":"J Clin Oncol"},{"issue":"6","key":"8_CR42","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781\u201392.","journal-title":"Lancet Oncol"},{"key":"8_CR43","unstructured":"Roche. Roche provides update on phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer [Internet]. 2024 [cited 2025 Mar 3]. Available from: www.roche.com\/media\/releases\/med-cor-2024-11-26"},{"key":"8_CR44","unstructured":"Genentech. Genentech provides update of phase 2\/3 Skyscraper-06 study in metastatic nonsquamous non\u2013small cell lung cancer [Internet]. [cited 2025 Mar 3]. Available from: https:\/\/www.gene.com\/media\/press-releases\/15029\/2024-07-03\/genentech-provides-update-on-phase"},{"issue":"9","key":"8_CR45","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","volume":"172","author":"CJ Workman","year":"2004","unstructured":"Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DAA. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo1. J Immunol. 2004;172(9):5450\u20135.","journal-title":"J Immunol"},{"issue":"4","key":"8_CR46","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","volume":"21","author":"CT Huang","year":"2004","unstructured":"Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503\u201313.","journal-title":"Immunity"},{"issue":"7","key":"8_CR47","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1002\/eji.200526090","volume":"35","author":"M Kisielow","year":"2005","unstructured":"Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol. 2005;35(7):2081\u20138.","journal-title":"Eur J Immunol"},{"issue":"16_suppl","key":"8_CR48","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.1200\/JCO.2022.40.16_suppl.9003","volume":"40","author":"E Felip","year":"2022","unstructured":"Felip E, Majem M, Doger B, Clay TD, Carcereny E, Bondarenko I, et al. A phase II study (TACTI-002) in first-line metastatic non\u2013small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: updated results from a PD-L1 unselected population. J Clin Oncol. 2022;40(16_suppl):9003.","journal-title":"J Clin Oncol"},{"issue":"11","key":"8_CR49","volume":"5","author":"MG Krebs","year":"2024","unstructured":"Krebs MG, Forster M, Majem M, Peguero J, Iams W, Clay T, et al. Eftilagimod alpha (a soluble LAG-3 protein) combined with pembrolizumab in second-line metastatic NSCLC refractory to anti\u2013programmed cell death protein 1\/programmed death-ligand 1-based therapy: final results from a phase 2 study. JTO Clin Res Rep. 2024;5(11):100725.","journal-title":"JTO Clin Res Rep"},{"issue":"10","key":"8_CR50","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00262-012-1237-1","volume":"61","author":"TS Fisher","year":"2012","unstructured":"Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother. 2012;61(10):1721\u201333.","journal-title":"Cancer Immunol Immunother"},{"issue":"18","key":"8_CR51","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-17-1243","volume":"23","author":"AW Tolcher","year":"2017","unstructured":"Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, et al. Phase Ib study of utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors. Clin Cancer Res. 2017;23(18):5349\u201357.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"8_CR52","volume":"6","author":"S Sapski","year":"2017","unstructured":"Sapski S, Beha N, Kontermann R, M\u00fcller D. Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors. Onco Targets Ther. 2017;6(12):e1361594.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"8_CR53","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10555-024-10184-9","volume":"43","author":"B Thapa","year":"2024","unstructured":"Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, et al. OX40\/OX40 ligand and its role in precision immune oncology. Cancer Metastasis Rev. 2024;43(3):1001\u201313.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"8_CR54","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s40425-019-0827-2","volume":"7","author":"E Massarelli","year":"2019","unstructured":"Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, et al. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. J Immunother Cancer. 2019;7(1):351.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"8_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005301","volume":"11","author":"S Postel-Vinay","year":"2023","unstructured":"Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC, et al. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J Immunother Cancer. 2023;11(3):e005301.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"8_CR56","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","volume":"2","author":"P M\u00fcller","year":"2014","unstructured":"M\u00fcller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, et al. Microtubule-depolymerizing agents used in antibody\u2013drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res. 2014;2(8):741\u201355.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"8_CR57","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","volume":"77","author":"J Rios-Doria","year":"2017","unstructured":"Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, et al. Antibody\u2013drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies. Cancer Res. 2017;77(10):2686\u201398.","journal-title":"Cancer Res"},{"issue":"7","key":"8_CR58","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1158\/0008-5472.CAN-20-0434","volume":"81","author":"J Boshuizen","year":"2021","unstructured":"Boshuizen J, Pencheva N, Krijgsman O, Altimari DD, Castro PG, De Bruijn B, et al. Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody\u2013drug conjugate and immune checkpoint blockade. Cancer Res. 2021;81(7):1775\u201387.","journal-title":"Cancer Res"},{"issue":"1","key":"8_CR59","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Zhang J, Li A, Niu M, Yan Y, Jiao Y, et al. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1. J Hematol Oncol. 2021;14(1):27.","journal-title":"J Hematol Oncol"},{"issue":"16","key":"8_CR60","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"B Aditya","year":"2021","unstructured":"Aditya B, Hurvitz SA, Tolaney SM, Delphine L, Kevin P, Mafalda O, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"8_CR61","doi-asserted-by":"publisher","first-page":"TPS9105","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9105","volume":"36","author":"ML Johnson","year":"2018","unstructured":"Johnson ML, Solomon BJ, Awad MM, Cho BC, Gainor JF, Goldberg SB, et al. MORPHEUS: a phase Ib\/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol. 2018;36(15_suppl):TPS9105.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"8_CR62","doi-asserted-by":"publisher","first-page":"TPS9146","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9146","volume":"40","author":"EB Garon","year":"2022","unstructured":"Garon EB, Liu SV, Owen SP, Reck M, Neal JW, Vicente D, et al. EVOKE-02: a phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non\u2013small cell lung cancer (NSCLC). J Clin Oncol. 2022;40(16_suppl):TPS9146.","journal-title":"J Clin Oncol"},{"issue":"11","key":"8_CR63","doi-asserted-by":"publisher","first-page":"S305","DOI":"10.1016\/j.jtho.2023.09.525","volume":"18","author":"C Aggarwal","year":"2023","unstructured":"Aggarwal C, Cheema P, Arrieta O, Bonanno L, Borghaei H, Hu Y, et al. P2.04-02 AVANZAR: phase III study of datopotamab deruxtecan (dato-DXd) + durvalumab + carboplatin as 1L treatment of advanced\/mNSCLC. J Thorac Oncol. 2023;18(11):S305\u20136.","journal-title":"J Thorac Oncol"},{"issue":"16_suppl","key":"8_CR64","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1200\/JCO.2023.41.16_suppl.9004","volume":"41","author":"Y Goto","year":"2023","unstructured":"Goto Y, Su WC, Levy BP, Rixe O, Yang TY, Tolcher AW, et al. TROPION-Lung02: datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). J Clin Oncol. 2023;41(16_suppl):9004.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"8_CR65","doi-asserted-by":"publisher","first-page":"TPS1100","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS1100","volume":"38","author":"H Borghaei","year":"2020","unstructured":"Borghaei H, Besse B, Bardia A, Mazieres J, Popat S, Augustine B, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced\/metastatic breast or non-small cell lung cancer (NSCLC): a phase Ib, multicenter, study. J Clin Oncol. 2020;38(15_suppl):TPS1100.","journal-title":"J Clin Oncol"},{"issue":"3","key":"8_CR66","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1158\/1535-7163.MCT-23-0310","volume":"23","author":"A Doug\u00e9","year":"2024","unstructured":"Doug\u00e9 A, El Ghazzi N, Lemal R, Rouzaire P. Adoptive T cell therapy in solid tumors: state-of-the art, current challenges, and upcoming improvements. Mol Cancer Ther. 2024;23(3):272\u201384.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"8_CR67","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-023-01926-4","volume":"23","author":"Y Li","year":"2024","unstructured":"Li Y, Sharma A, Schmidt-Wolf IGH. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1\/PD-L1 blockade in the clinical spectrum of lung cancer. Mol Cancer. 2024;23(1):80.","journal-title":"Mol Cancer"},{"issue":"1","key":"8_CR68","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40164-024-00506-6","volume":"13","author":"MY Xu","year":"2024","unstructured":"Xu MY, Zeng N, Liu CQ, Sun JX, An Y, Zhang SH, et al. Enhanced cellular therapy: revolutionizing adoptive cellular therapy. Exp Hematol Oncol. 2024;13(1):47.","journal-title":"Exp Hematol Oncol"},{"issue":"6230","key":"8_CR69","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62\u20138.","journal-title":"Science"},{"key":"8_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.973881","volume":"13","author":"B Li","year":"2022","unstructured":"Li B. Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors? Front Immunol. 2022;13:973881.","journal-title":"Front Immunol"},{"issue":"8","key":"8_CR71","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","volume":"14","author":"AJ Schoenfeld","year":"2024","unstructured":"Schoenfeld AJ, Lee SM, Doger de Sp\u00e9ville B, Gettinger SN, H\u00e4fliger S, Sukari A, et al. Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non\u2013small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discov. 2024;14(8):1389\u2013402.","journal-title":"Cancer Discov"},{"issue":"8","key":"8_CR72","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27(8):1410\u20138.","journal-title":"Nat Med"},{"issue":"15_suppl","key":"8_CR73","doi-asserted-by":"publisher","first-page":"TPS3107","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3107","volume":"36","author":"SM Lee","year":"2018","unstructured":"Lee SM, Haigentz M, Villaruz LC, Gorbatchevsky I, Suzuki S, Tanamly S, et al. A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC. J Clin Oncol. 2018;36(15_suppl):TPS3107.","journal-title":"J Clin Oncol"},{"issue":"16","key":"8_CR74","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1158\/1078-0432.CCR-17-1788","volume":"24","author":"P Gulati","year":"2018","unstructured":"Gulati P, R\u00fchl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, et al. Aberrant Lck signal via CD28 costimulation augments antigen-specific functionality and tumor control by redirected T cells with PD-1 blockade in humanized mice. Clin Cancer Res. 2018;24(16):3981\u201393.","journal-title":"Clin Cancer Res"},{"key":"8_CR75","first-page":"1","volume":"187","author":"M Zeltsman","year":"2017","unstructured":"Zeltsman M, Dozier J, McGee E, Ngai D, Adusumilli PS. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma. Depth Rev Chimeric Antigen Recept T Cell-Based Ther. 2017;187:1\u201310.","journal-title":"Depth Rev Chimeric Antigen Recept T Cell-Based Ther"},{"issue":"11","key":"8_CR76","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748\u201363.","journal-title":"Cancer Discov"},{"issue":"5","key":"8_CR77","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","volume":"59","author":"K Feng","year":"2016","unstructured":"Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer. Sci China Life Sci. 2016;59(5):468\u201379.","journal-title":"Sci China Life Sci"},{"issue":"4","key":"8_CR78","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843\u201351.","journal-title":"Mol Ther"},{"issue":"7","key":"8_CR79","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9(7):eadf3700.","journal-title":"Sci Adv"},{"issue":"29","key":"8_CR80","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","volume":"35","author":"YC Lu","year":"2017","unstructured":"Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, et al. Treatment of patients with metastatic cancer using a major histocompatibility complex class II\u2013restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. J Clin Oncol. 2017;35(29):3322\u20139.","journal-title":"J Clin Oncol"},{"issue":"7953","key":"8_CR81","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2023;615(7953):687\u201396.","journal-title":"Nature"},{"issue":"1","key":"8_CR82","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003581","volume":"10","author":"GR Blumenschein","year":"2022","unstructured":"Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, et al. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer. J Immunother Cancer. 2022;10(1):e003581.","journal-title":"J Immunother Cancer"},{"key":"8_CR83","doi-asserted-by":"publisher","unstructured":"Veatch J, Paulson K, Asano Y, Martin L, Lee B, Hall ET, et al. Merkel polyoma virus specific T-cell receptor transgenic T-cell therapy in PD-1 inhibitor refractory Merkel cell carcinoma. J Clin Oncol. 2022; https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.954.","DOI":"10.1200\/JCO.2022.40.16_suppl.954"},{"issue":"15","key":"8_CR84","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.7150\/ijbs.76281","volume":"18","author":"Z Liu","year":"2022","unstructured":"Liu Z, Lv J, Dang Q, Liu L, Weng S, Wang L, et al. Engineering neoantigen vaccines to improve cancer personalized immunotherapy. Int J Biol Sci. 2022;18(15):5607\u201323.","journal-title":"Int J Biol Sci"},{"key":"8_CR85","doi-asserted-by":"publisher","first-page":"1105420","DOI":"10.3389\/fimmu.2023.1105420","volume":"14","author":"N Biswas","year":"2023","unstructured":"Biswas N, Chakrabarti S, Padul V, Jones LD, Ashili S. Designing neoantigen cancer vaccines, trials, and outcomes. Front Immunol. 2023;14:1105420.","journal-title":"Front Immunol"},{"issue":"3","key":"8_CR86","first-page":"392","volume":"16","author":"SY Ho","year":"2023","unstructured":"Ho SY, Chang CM, Liao HN, Chou WH, Guo CL, Yen Y, et al. Current trends in neoantigen-based cancer vaccines. Pharm Basel (Switz). 2023;16(3):392.","journal-title":"Pharm Basel (Switz)"},{"issue":"1","key":"8_CR87","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"8_CR88","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jtho.2021.01.1624","volume":"16","author":"L Ye","year":"2021","unstructured":"Ye L, Creaney J, Redwood A, Robinson B. The current lung cancer neoantigen landscape and implications for therapy. J Thorac Oncol. 2021;16(6):922\u201332.","journal-title":"J Thorac Oncol"},{"issue":"6230","key":"8_CR89","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science"},{"issue":"5","key":"8_CR90","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","volume":"33","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell. 2018;33(5):843\u2013852.e4.","journal-title":"Cancer Cell"},{"issue":"9","key":"8_CR91","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. 2022;40(9):1010\u20131026.e11.","journal-title":"Cancer Cell"},{"key":"8_CR92","doi-asserted-by":"publisher","unstructured":"Lou Y. A phase I pilot study of personalized neoantigen peptide-based vaccine in combination with pembrolizumab in advanced solid tumors (PNeoVCA). J Clin Oncol. 2024; https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.954.","DOI":"10.1200\/JCO.2022.40.16_suppl.954"},{"issue":"8","key":"8_CR93","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/mt.2010.98","volume":"18","author":"BW Bridle","year":"2010","unstructured":"Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther. 2010;18(8):1430\u20139.","journal-title":"Mol Ther"},{"issue":"2","key":"8_CR94","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/mt.2013.249","volume":"22","author":"JG Pol","year":"2014","unstructured":"Pol JG, Zhang L, Bridle BW, Stephenson KB, Ress\u00e9guier J, Hanson S, et al. Maraba virus as a potent oncolytic vaccine vector. Mol Ther. 2014;22(2):420\u20139.","journal-title":"Mol Ther"},{"issue":"1","key":"8_CR95","volume":"8","author":"JG Pol","year":"2019","unstructured":"Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, et al. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Onco Targets Ther. 2019;8(1):e1512329.","journal-title":"Onco Targets Ther"},{"issue":"15_suppl","key":"8_CR96","doi-asserted-by":"publisher","first-page":"e14637","DOI":"10.1200\/JCO.2017.35.15_suppl.e14637","volume":"35","author":"DJ Jonker","year":"2017","unstructured":"Jonker DJ, Hotte SJ, Abdul Razak AR, Renouf DJ, Lichty B, Bell JC, et al. Phase I study of oncolytic virus (OV) MG1 maraba\/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced\/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214. J Clin Oncol. 2017;35(15_suppl):e14637.","journal-title":"J Clin Oncol"},{"issue":"5","key":"8_CR97","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/vaccines12050498","volume":"12","author":"K Kumari","year":"2024","unstructured":"Kumari K, Singh A, Chaudhary A, Singh RK, Shanker A, Kumar V, et al. Neoantigen identification and dendritic cell-based vaccines for lung cancer immunotherapy. Vaccine. 2024;12(5):498.","journal-title":"Vaccine"},{"issue":"305","key":"8_CR98","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","volume":"26","author":"RH Mole","year":"1953","unstructured":"Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234\u201341.","journal-title":"Br J Radiol"},{"issue":"1","key":"8_CR99","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/ijms15010927","volume":"15","author":"B Park","year":"2014","unstructured":"Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci. 2014;15(1):927\u201343.","journal-title":"Int J Mol Sci"},{"issue":"7547","key":"8_CR100","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373\u20137.","journal-title":"Nature"},{"issue":"13","key":"8_CR101","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498\u2013509.","journal-title":"Lancet Oncol"},{"issue":"4","key":"8_CR102","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic radiation therapy augments antigen-specific PD-1\u2013mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015;3(4):345\u201355.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"8_CR103","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/cac2.12226","volume":"41","author":"S Shang","year":"2021","unstructured":"Shang S, Liu J, Verma V, Wu M, Welsh J, Yu J, et al. Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. Cancer Commun. 2021;41(11):1086\u201399.","journal-title":"Cancer Commun"},{"key":"8_CR104","doi-asserted-by":"crossref","unstructured":"Chamoto K, Chowdhury PS, Kumar A, Sonomura K, Matsuda F, Fagarasan S, et al. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci [Internet]. 2017 [cited 2024 Jun 23];114(5). Available from: https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1620433114","DOI":"10.1073\/pnas.1620433114"},{"issue":"9","key":"8_CR105","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Demaria","year":"2015","unstructured":"Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325\u201332.","journal-title":"JAMA Oncol"},{"issue":"11","key":"8_CR106","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","volume":"24","author":"TM Ashton","year":"2018","unstructured":"Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24(11):2482\u201390.","journal-title":"Clin Cancer Res"},{"key":"8_CR107","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.envres.2018.01.027","volume":"163","author":"M Le","year":"2018","unstructured":"Le M, McNeill FE, Seymour CB, Rusin A, Diamond K, Rainbow AJ, et al. Modulation of oxidative phosphorylation (OXPHOS) by radiation- induced biophotons. Environ Res. 2018;163:80\u20137.","journal-title":"Environ Res"},{"issue":"2","key":"8_CR108","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/annonc\/mdx790","volume":"29","author":"T Kordbacheh","year":"2018","unstructured":"Kordbacheh T, Honeychurch J, Blackhall F, Faivre-Finn C, Illidge T. Radiotherapy and anti-PD-1\/PD-L1 combinations in lung cancer: building better translational research platforms. Ann Oncol. 2018;29(2):301\u201310.","journal-title":"Ann Oncol"},{"issue":"9","key":"8_CR109","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"WSME Theelen","year":"2019","unstructured":"Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276\u201382.","journal-title":"JAMA Oncol"},{"issue":"2","key":"8_CR110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001001","volume":"8","author":"J Welsh","year":"2020","unstructured":"Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial. J Immunother Cancer. 2020;8(2):e001001.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"8_CR111","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"WSME Theelen","year":"2021","unstructured":"Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021;9(5):467\u201375.","journal-title":"Lancet Respir Med"},{"issue":"20","key":"8_CR112","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"11","key":"8_CR113","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1001\/jamaoncol.2023.3309","volume":"9","author":"M Tachihara","year":"2023","unstructured":"Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, et al. Durvalumab plus concurrent radiotherapy for treatment of locally advanced non\u2013small cell lung cancer: the DOLPHIN phase 2 nonrandomized controlled trial. JAMA Oncol. 2023;9(11):1505.","journal-title":"JAMA Oncol"},{"issue":"9","key":"8_CR114","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","volume":"5","author":"JM Bauml","year":"2019","unstructured":"Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non\u2013small cell lung cancer: a phase 2 trial. JAMA Oncol. 2019;5(9):1283.","journal-title":"JAMA Oncol"},{"issue":"6","key":"8_CR115","volume":"5","author":"DJ Cantor","year":"2024","unstructured":"Cantor DJ, Davis C, Ciunci C, Aggarwal C, Evans T, Cohen RB, et al. Brief report: long-term follow-up of adjuvant pembrolizumab after locally ablative therapy for oligometastatic NSCLC. JTO Clin Res Rep. 2024;5(6):100667.","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"8_CR116","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/gtmb.2018.0211","volume":"24","author":"EM Lancaster","year":"2020","unstructured":"Lancaster EM, Jablons D, Kratz JR. Applications of next-generation sequencing in neoantigen prediction and cancer vaccine development. Genet Test Mol Biomark. 2020;24(2):59\u201366.","journal-title":"Genet Test Mol Biomark"},{"issue":"9","key":"8_CR117","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.3390\/cancers14092157","volume":"14","author":"DWK Chan","year":"2022","unstructured":"Chan DWK, Choi HCW, Lee VHF. Treatment-related adverse events of combination EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor in EGFR-mutant advanced non-small cell lung cancer: a systematic review and meta-analysis. Cancer. 2022;14(9):2157.","journal-title":"Cancer"},{"issue":"1","key":"8_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","volume":"17","author":"Q Wei","year":"2024","unstructured":"Wei Q, Li P, Yang T, Zhu J, Sun L, Zhang Z, et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024;17(1):1.","journal-title":"J Hematol Oncol"},{"key":"8_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102179","volume":"96","author":"A Addeo","year":"2021","unstructured":"Addeo A, Passaro A, Malapelle U, Banna GL, Subbiah V, Friedlaender A. Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treat Rev. 2021;96:102179.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"8_CR120","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","volume":"2","author":"J McLaughlin","year":"2016","unstructured":"McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non\u2013small-cell lung cancer. JAMA Oncol. 2016;2(1):46\u201354.","journal-title":"JAMA Oncol"},{"issue":"2","key":"8_CR121","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.lungcan.2014.05.005","volume":"85","author":"R Sundar","year":"2014","unstructured":"Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer. 2014;85(2):101\u20139.","journal-title":"Lung Cancer"},{"issue":"18","key":"8_CR122","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-07-1030","volume":"13","author":"X Zang","year":"2007","unstructured":"Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 2007;13(18):5271\u20139.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"8_CR123","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","volume":"41","author":"X Meng","year":"2015","unstructured":"Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 2015;41(10):868\u201376.","journal-title":"Cancer Treat Rev"}],"container-title":["Cancer Treatment and Research","Immunotherapies in Solid Tumors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-97242-3_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:04:51Z","timestamp":1778886291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-97242-3_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031972416","9783031972423"],"references-count":123,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-97242-3_8","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-3-031-97242-3","asserted-by":"object"}]},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"23 August 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}